Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

Stopped early · Not applicable

Conditions studied: Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C

In brief

The purpose of this study is to determine whether obese people do not respond to hepatitis C treatment as well as lean people. This research studies whether obese people will show higher sustained virologic response rate if they lose weight by Orlistat use and dietary and lifestyle modification.

Key facts

Study ID

NCT00871845

Run by

Hossam Kandil

People needed

36

Starts

2008-09-01

Expected to finish

2011-08-01

Last updated by the study team

2018-11-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 years or older
• positive diagnosis of hepatitis C, by Polymerase Chain Reaction (PCR
• scheduled to start treatment of hepatitis C by peg interferon and ribavirin
• agreeing to give a written consent to participate in this study.

You may not qualify if…

• patients under 18 years of age
• refusal to give a consent to participate in the study
• history of recreational drug or alcohol use in the preceding 6 months
• pregnancy by hCG pregnancy testing which will be done prior to and monthly during the 12 month hepatitis C therapy and for 6 months following the end of treatment
• plan for pregnancy during the study period
• failure to adhere to contraceptive methods
• HIV disease
• evidence of cirrhosis or confirmed hepatocellular carcinoma (HCC), evidence of decompensated liver disease or presence of other liver diseases such as hepatitis B, hemochromatosis, autoimmune hepatitis and Wilson disease
• Patients will be removed from the study if they develop severe side effects to IFN (e.g marked depression, autoimmune reactions like thyroiditis, aplastic anemia..), severe side effects to ribavirin (e.g. marked hemolysis) or intolerance of Orlistat/placebo (e.g. allergic reaction, diarrhea, flatulence..) and withdrawal of the consent.

Where it is running

• Center for Liver Diseases, UPMC. — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.